Curran D[au] - Search Results

Year	Number of Results
1930	1
1934	1
1939	1
1941	1
1944	1
1951	2
1952	2
1953	1
1954	1
1955	1
1956	1
1957	1
1958	1
1961	3
1963	2
1964	3
1965	2
1972	1
1973	1
1974	1
1975	1
1976	1
1977	3
1978	2
1980	2
1983	1
1984	6
1985	4
1986	3
1987	4
1989	4
1990	1
1991	1
1992	6
1993	2
1994	3
1996	5
1997	10
1998	16
1999	8
2000	16
2001	9
2002	19
2003	14
2004	16
2005	21
2006	19
2007	12
2008	15
2009	21
2010	27
2011	23
2012	24
2013	35
2014	27
2015	25
2016	19
2017	25
2018	25
2019	29
2020	27
2021	28
2022	22
2023	23
2024	15

1

Rational selection of TbpB variants elucidates a bivalent vaccine formulation with broad spectrum coverage against Neisseria gonorrhoeae.

Fegan JE, Islam EA, Curran DM, Ng D, Au N, Currie EG, Zeppa J, Lam J, Schryvers AB, Moraes TF, Gray-Owen SD. Fegan JE, et al. Among authors: curran dm. bioRxiv [Preprint]. 2024 Sep 7:2024.09.07.611798. doi: 10.1101/2024.09.07.611798. bioRxiv. 2024. PMID: 39282273 Free PMC article. Preprint.

2

The Incidence of Herpes Zoster Complications: A Systematic Literature Review.

Giannelos N, Curran D, Nguyen C, Kagia C, Vroom N, Vroling H. Giannelos N, et al. Among authors: curran d. Infect Dis Ther. 2024 Jul;13(7):1461-1486. doi: 10.1007/s40121-024-01002-4. Epub 2024 Jun 19. Infect Dis Ther. 2024. PMID: 38896390 Free PMC article. Review.

3

Prevalence of Slam-dependent hemophilins in Gram-negative bacteria.

Shin HE, Pan C, Curran DM, Bateman TJ, Chong DHY, Ng D, Shah M, Moraes TF. Shin HE, et al. Among authors: curran dm. J Bacteriol. 2024 Jun 20;206(6):e0002724. doi: 10.1128/jb.00027-24. Epub 2024 May 30. J Bacteriol. 2024. PMID: 38814789

4

Herpes zoster in older adults: Impact on carbon footprint in the United States.

Curran D, Bitetti J, Catterall I, Wincott S. Curran D, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2335722. doi: 10.1080/21645515.2024.2335722. Epub 2024 May 3. Hum Vaccin Immunother. 2024. PMID: 38698759 Free PMC article.

5

Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials.

Giannelos N, Francq B, Curran D. Giannelos N, et al. Among authors: curran d. Clin Drug Investig. 2024 May;44(5):293-301. doi: 10.1007/s40261-024-01355-1. Epub 2024 Apr 25. Clin Drug Investig. 2024. PMID: 38662318 Free PMC article.

6

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.

Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin YC, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T. Neal J, et al. Among authors: curran d. J Clin Oncol. 2024 Jul 10;42(20):2393-2403. doi: 10.1200/JCO.23.02166. Epub 2024 Mar 29. J Clin Oncol. 2024. PMID: 38552197 Free PMC article. Clinical Trial.

7

Neurocognitive functioning among children and young people with Duchenne Muscular Dystrophy: A systematic review and meta-analysis.

Gregg J, Wilson C, Curran D, Hanna D. Gregg J, et al. Among authors: curran d. Clin Neuropsychol. 2024 Mar 20:1-28. doi: 10.1080/13854046.2024.2324500. Online ahead of print. Clin Neuropsychol. 2024. PMID: 38509463 Review.

8

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States.

Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Molnar D, et al. Among authors: curran d. Infect Dis Ther. 2024 Apr;13(4):827-844. doi: 10.1007/s40121-024-00939-w. Epub 2024 Mar 20. Infect Dis Ther. 2024. PMID: 38507143 Free PMC article.

9

The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review.

Parikh R, Yousefi M, Curran D, Widenmaier R. Parikh R, et al. Among authors: curran d. Infect Dis Ther. 2024 Mar;13(3):447-461. doi: 10.1007/s40121-024-00924-3. Epub 2024 Mar 5. Infect Dis Ther. 2024. PMID: 38441844 Free PMC article. Review.

10

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.

Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Yau T, et al. Among authors: curran d. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

593 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

593 results

Results by year